These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

761 related items for PubMed ID: 9781950

  • 1. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
    Diamond T, Campbell J, Bryant C, Lynch W.
    Cancer; 1998 Oct 15; 83(8):1561-6. PubMed ID: 9781950
    [Abstract] [Full Text] [Related]

  • 2. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study.
    Diamond TH, Winters J, Smith A, De Souza P, Kersley JH, Lynch WJ, Bryant C.
    Cancer; 2001 Sep 15; 92(6):1444-50. PubMed ID: 11745221
    [Abstract] [Full Text] [Related]

  • 3. A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men.
    Egawa S, Takashima R, Matsumoto K, Mizoguchi H, Kuwao S, Baba S.
    Jpn J Clin Oncol; 2000 Jan 15; 30(1):21-6. PubMed ID: 10770564
    [Abstract] [Full Text] [Related]

  • 4. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
    Struys A, Snelder AA, Mulder H.
    Am J Med; 1995 Sep 15; 99(3):235-42. PubMed ID: 7653482
    [Abstract] [Full Text] [Related]

  • 5. Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.
    Yu EY, Kuo KF, Gulati R, Chen S, Gambol TE, Hall SP, Jiang PY, Pitzel P, Higano CS.
    J Clin Oncol; 2012 May 20; 30(15):1864-70. PubMed ID: 22493411
    [Abstract] [Full Text] [Related]

  • 6. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy.
    Fujita T, Satomura A, Hidaka M, Ohsawa I, Endo M, Ohi H.
    Calcif Tissue Int; 2000 Mar 20; 66(3):195-9. PubMed ID: 10666494
    [Abstract] [Full Text] [Related]

  • 7. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.
    Prostate Cancer Prostatic Dis; 2002 Mar 20; 5(4):304-10. PubMed ID: 12627216
    [Abstract] [Full Text] [Related]

  • 8. Predictors of bone mass in healthy older men in the community.
    Smerdely P, Seller M, Smith A, Day P, Diamond T.
    Med J Aust; 2000 Aug 21; 173(4):183-6. PubMed ID: 11008590
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.
    Diamond T, McGuigan L, Barbagallo S, Bryant C.
    Am J Med; 1995 May 21; 98(5):459-63. PubMed ID: 7733124
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
    Choo R, Lukka H, Cheung P, Corbett T, Briones-Urbina R, Vieth R, Ehrlich L, Kiss A, Danjoux C.
    Int J Radiat Oncol Biol Phys; 2013 Apr 01; 85(5):1239-45. PubMed ID: 23265571
    [Abstract] [Full Text] [Related]

  • 15. Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures.
    Anderson FH, Francis RM, Bishop JC, Rawlings DJ.
    Age Ageing; 1997 Sep 01; 26(5):359-65. PubMed ID: 9351480
    [Abstract] [Full Text] [Related]

  • 16. Intermittent Etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist.
    Zamberlan N, Castello R, Gatti D, Rossini M, Braga V, Fracassi E, Adami S.
    Osteoporos Int; 1997 Sep 01; 7(2):133-7. PubMed ID: 9166393
    [Abstract] [Full Text] [Related]

  • 17. [Administration of 1 alpha-OH vitamin D3 and calcium prevents bone mass loss in patients with advanced prostatic carcinoma after orchidectomy treated with complete androgenic blockade].
    Tałalaj M, Kapitan-Malinowska B, Debski K, Nowakowski R, Marcinowska-Suchowierska E, Witeska A.
    Endokrynol Pol; 2005 Sep 01; 56(3):225-32. PubMed ID: 16350714
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
    Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS.
    N Engl J Med; 2001 Sep 27; 345(13):948-55. PubMed ID: 11575286
    [Abstract] [Full Text] [Related]

  • 20. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
    Leibowitz RL, Tucker SJ.
    Oncologist; 2001 Sep 27; 6(2):177-82. PubMed ID: 11306729
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.